

**CAMP4 THERAPEUTICS CORPORATION**

One Kendall Square  
Building 1400 West, 3<sup>rd</sup> Floor  
Cambridge, Massachusetts 02139

October 8, 2024

**VIA EDGAR**

Securities and Exchange Commission  
Division of Corporate Finance  
100 F Street, N.E.  
Washington, D.C. 20549

Attention: Lauren Sprague Hammill, Division of Corporation Finance

Re: CAMP4 Therapeutics Corporation  
Registration Statement on Form S-1, as amended (File No. 333-282241)  
Request for Acceleration

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, CAMP4 Therapeutics Corporation, a Delaware corporation (the "Company"), hereby requests that the effective date for the registration statement referred to above be accelerated so that it will be declared effective at 4:00 p.m. Eastern Time on October 10, 2024, or as soon as possible thereafter. The Company hereby authorizes Thomas Danielski or Lisa Folkerth of Ropes & Gray LLP, counsel to the Company, to orally modify or withdraw this request for acceleration.

Please call Thomas Danielski or Lisa Folkerth of Ropes & Gray LLP, counsel to the Company, at (617) 235-4961 or (617) 951-7791 as soon as the registration statement has been declared effective.

*[Signature page follows]*

---

Very truly yours,

CAMP4 THERAPEUTICS CORPORATION

By: /s/ Josh Mandel-Brehm

Name: Josh Mandel-Brehm

Title: Chief Executive Officer

- cc. Josh Mandel-Brehm (CAMP4 Therapeutics Corporation)
  - cc. Thomas Danielski (Ropes & Gray LLP)
  - cc. Lisa Folkerth (Ropes & Gray LLP)
  - cc. Siavosh Salimi (Paul Hastings LLP)
  - cc. William A. Magioncalda (Paul Hastings LLP)
-